Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 5Small Cell Lung Carcinoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 3Head and Neck Neoplasms 3Gallbladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, Follicular 2Glioma 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1TNBC 1Stomatitis 1Stomach Neoplasms 1Squamous Intraepithelial Lesions 1Smoldering Multiple Myeloma 1Recurrence 1Parkinsonian Disorders 1Pancreatic Neoplasms 1Pancreatic Cancer Non-resectable 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Nasopharyngeal Neoplasms 1

Interventions

Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Enrolling by invitation × Pancreatic Cancer Non-resectable × Clear all
NCT07386704 2026-02-04

Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer

Peking University First Hospital

Phase 2 Enrolling by invitation
30 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡